Molecular Partners (NASDAQ:MOLN) Stock Price Down 2.1% - Here's What Happened

Key Points

• Molecular Partners AG stock fell by 2.1% to last trade at $3.81, with trading volume down by 70% compared to its average.
• Analysts have issued mixed ratings, with one Buy, one Hold, and one Sell rating, while the consensus price target stands at $8.00.
• The company reported a loss of ($0.67) EPS for the last quarter, missing estimates by ($0.14).

Molecular Partners AG Sponsored ADR (NASDAQ:MOLN - Get Free Report) dropped 2.1% on Friday . The company traded as low as $3.68 and last traded at $3.81. Approximately 808 shares changed hands during mid-day trading, a decline of 70% from the average daily volume of 2,654 shares. The stock had previously closed at $3.89.

Analyst Ratings Changes

MOLN has been the subject of a number of analyst reports. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Molecular Partners in a report on Saturday, September 27th. JPMorgan Chase & Co. cut their price objective on Molecular Partners from $4.50 to $4.00 and set a "neutral" rating for the company in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Molecular Partners has a consensus rating of "Hold" and a consensus price target of $8.00.

Molecular Partners Stock Performance

The company has a 50 day simple moving average of $3.71 and a 200 day simple moving average of $3.79. The company has a market capitalization of $153.85 million, a PE ratio of -1.83 and a beta of 1.09.

Molecular Partners (NASDAQ:MOLN - Get Free Report) last posted its quarterly earnings data on Monday, August 25th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.14). As a group, equities research analysts anticipate that Molecular Partners AG Sponsored ADR will post -1.93 EPS for the current year.

About Molecular Partners

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.